MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
6. Technology Transfer (T2), NonDilutive Funding: Strategy Development
* T2ToolBox
Triple Helix: Reports, Publications & Metrics
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Ireland
Avadel Pharmaceuticals plc (NASDAQ:AVDL)*
Organization & Developments: Avadel
Parents
Avadel Pharmaceuticals plc (NASDAQ:AVDL)*
Children
2020: Assessing An Investment In Avadel Pharmaceuticals
2020: Avadel's Xyrem Competitor: A Quick Overview
2021: Avadel Pharmaceuticals: I Am Holding
2022: Avadel And Jazz: The Oxybate Wars - Duking It Out_ seekingalpha.com
2022: Avadel Pharmaceuticals: Navigating Through The Uncertainty_seekingalpha.com
2022: Avadel's LUMRYZ: A Good Night's Sleep For Narcolepsy Patients_seekingalpha.com
2022: With narcolepsy approval a year out, antsy Avadel slashes staff by 50%
2023: Assessing Avadel's Lumryz: Clinical Innovation Versus Economic Realities (NASDAQ:AVDL)
2023: Avadel Pharmaceuticals' Strategic Moves To Conquer The Narcolepsy Market (Rating Upgrade)_ seekingalpha.com
2024: Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky_seekingalpha.com
2024: Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
2024: Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop_seekingalpha
2024: Avadel wins FDA approval for narcolepsy drug Lumryz in children
2025: Avadel gets FDA's Orphan Drug status for sleep disorder treatment
2025: Avadel Pharmaceuticals plc 2024 Q4 - Results - Earnings Call Presentation
2025: Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'
2025: Avadel Pharmaceuticals: Moving To A Speculative Buy
2025: Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook_seekingalpha.com
Jumps
Finance & Acquisitions: Avadel
Key People: Avadel